REFERENCES
D. A. Griffith and S. M. Jarvis. Nucleoside and nucleobase transport systems of mammalian cells. Biochim. Biophys. Acta 1286:153-181 (1996).
S. D. Patil and J. D. Unadkat. Sodium-dependent nucleoside transport in the human intestinal brush-border membrane. Am. J. Physiol. 272:G1314-1320 (1997).
G. Chandrasena, R. Giltay, S. D. Patil, A. Bakken, and J. D. Unadkat. Functional expression of human intestinal Na+-dependent and Na+-independent nucleoside transporters in the Xenopus laevis oocytes. Biochem. Pharm. 53:1909-18 (1997).
D. Vijayalakshmi and J. A. Belt. Sodium-dependent nucleoside transport in mouse intestinal epithelial cells. Two transport systems with differing substrate specificities. J. Biol. Chem. 263:19419-19423 (1988).
J. A. Belt, N. M. Marina, D. A. Phelps, and A. Crawford. Nucleoside transport in normal and neoplastic cells. Adv. Enzyme Regul. 33:235-252 (1993).
C. E. Cass. Nucleoside transport. In: N. H. Georgopapadakou (ed.), Drug Transport in Antimicrobial and Anticancer Chemotherapy, Marcel Decker, New York, 1995, pp. 403-451.
A. J. Mc Carthy, M. Bergin, L. M. De Silva, and M. Stevens. Intravenous ribavirin therapy for disseminated adenovirus infection. Ped. Inf. Dis. J. 14:1003-1004 (1995).
J. F. Hruska, J. M Bernstein, R. G. Douglas Jr., and C. B. Hall. Effects of ribavirin on respiratory syncytial virus in vitro. Agents Chemother. 17:770-775 (1980).
F. Kawana, S. Shigeta, and E. De Clercq. Inhibitory effects of several antiviral compounds on the replication of respiratory syncytial virus in vitro. Antiviral Res. 1:83-88 (1985).
O. L. Laskin, J. A. Longstreth, C. C. Hart, D. Scavuzzo, C. M. Kalman, J. D. Conners, and R. B. Roberts. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin. Pharmacol. Ther. 41:546-555 (1987).
J. J. L. Lertora, A. B. Rege, J. T. Lacour, N. Ferencz, W. J. George, R. B. VanDyke, K. C. Agrawal, and N. E. Hyslop, Jr. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 50:442-449 (1991).
R. Paroni, R. M. Del Puppo, C. Borght, C. R. Sirtori, and M. Gallikienle. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. Int. J. Clin. Pharmacol. Ther. Toxcol. 29:302-307 (1989).
H. Fernandez, G. Banks, and R. Smith. Ribavirin: A clinical overview. Eur. J. Epidemiol. 2:1-14 (1986).
B. Davies and T. Morris. Physiological parameters in laboratory animals and humans (editorial). Pharm. Res. 10:1093-95 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Patil, S.D., Ngo, L.Y., Glue, P. et al. Intestinal Absorption of Ribavirin Is Preferentially Mediated by the Na+-Nucleoside Purine (Nl) Transporter. Pharm Res 15, 950–952 (1998). https://doi.org/10.1023/A:1011945103455
Issue Date:
DOI: https://doi.org/10.1023/A:1011945103455